ArticleTherapeutics and clinical risk management2013
An update of teriflunomide for treatment of multiple sclerosis.
Article in Therapeutics and clinical risk management, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.The Cochrane database of systematic reviews · 2017Pooled it
- Comprehensive Identification and Mechanistic Evaluation of Novel DHODH Inhibitors as Potent Broad-Spectrum Antiviral Agents.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy.Microorganisms · 2022Review
- Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.Therapeutics and clinical risk management · 2020Review
- Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations.Therapeutic advances in chronic disease · 2020Article
- Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.Science translational medicine · 2019Article
- Unveiling some FDA-approved drugs as inhibitors of the store-operated CaScientific reports · 2017Article
- From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Current neuropharmacology · 2017Review
- An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.Brain and behavior · 2015Review
- [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Der Nervenarzt · 2015Article
- Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.Neurology(R) neuroimmunology & neuroinflammation · 2015Article
- Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.Advances in therapy · 2014Review
- Risk stratification and mitigation multiple sclerosis.Multiple sclerosis and related disorders · 2014Review
- Multiple sclerosis treatment and infectious issues: update 2013.Clinical and experimental immunology · 2014Review
- Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.Journal of virology · 2014Article
- Alemtuzumab in the treatment of multiple sclerosis.Journal of inflammation research · 2014Review
- Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.CNS drugs · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are a number of oral agents emerging as potential disease-modifying agents in multiple sclerosis (MS). Among these investigational agents, teriflunomide has shown promise in large, multicenter, phase III clinical trials with respect to safety and efficacy in relapsing MS patients, and is the latest disease-modifying agent approved for use in MS patients in the United States. This review will summarize teriflunomide's historical development, clinical pharmacology, studies in animals, clinical trials, and safety data, and will end with a discussion of the role of teriflunomide in MS in the context of existing treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.